Sign in
Taking people in United StatesNo phase

Studies how nerve signals affect blood pressure in adults with obesity

Tests whether vitamin C infusion changes nerve-driven blood vessel response in adults with obesity.

Key facts

Who runs it
University of Kansas Medical Center
Where
Kansas City, United StatesSee the site
Trial code
Registry title
Transduction of Sympathetic Neural Activity in Human Obesity Without Hypertension
Status
Recruiting
People taking part
60 people, planned
Started
1 Aug 2022
Expected to end
1 Sept 2027
Type of study
Observational
Treatments tested
  • ascorbic acid
Record updated
3 October 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for middle-aged adults with obesity and insulin resistance, without high blood pressure. It tests how a vitamin C drip changes the blood pressure response to nerve signals.

Age
35-65 years in the inclusion criteria (the registry header lists 18 Years to 79 Years).
Sex
All sexes can join.
Disease stage
Obesity (BMI >25 m/kg2) with raised insulin resistance (HOMA-IR > 2.5), without high blood pressure.
Earlier treatment
People must be willing to stop vitamin C or E supplements and omega-3 fatty acids 2 weeks before. People taking a statin or blood pressure medicine cannot join.
Biomarker or test result
HOMA-IR > 2.5, calculated from fasting glucose and insulin in the blood.

Main reasons for not taking part

  • Taking a statin or blood pressure medicine
  • Blood pressure above 130/80 mmHg
  • History of heart disease (for example heart attack, stent)
  • History of vascular disease (for example bypass, stroke)
  • Narrow angle glaucoma

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Obese: BMI >25 m/kg2
  • Elevated insulin resistance: HOMA-IR > 2.5 (calculation based on fasting glucose and insulin concentrations in blood)
  • Middle-aged: 35-65 years
  • Participants must be willing and able to discontinue taking any vitamin C or E supplements or omega-3 fatty acids beginning 2 weeks prior
  • Able and willing to provide written informed consent

Who cannot take part

  • Currently taking a statin or antihypertension medication
  • Hypertension: >130/80 mmHg
  • History of heart disease (e.g., myocardial infarction, stent)
  • History of vascular disease (e.g., bypass, stroke)
  • Hyperlipidemia: Fasting triglycerides < 250 mg/dL
  • Individuals with narrow angle glaucoma; -

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 79 years old?

Where in United States

  • University of Kansas Medical CenterKansas City, United StatesContact: Seth HolwerdaTaking people

About the trial

What the trial wants to find out

In addition to chronically elevated MSNA, there is a growing recognition that hypertension in states of insulin resistance and obesity may also be attributed to an increased vascular sensitivity to MSNA (1, 2, 13, 36-38). To study this phenomenon, we quantify vascular sensitivity to MSNA using an innovative, moment-to-moment assessment of the blood pressure response following individual bursts of muscle sympathetic nerve activity (MSNA), (10, 11, 34, 37). This approach is termed 'sympathetic-vascular transduction (SVT).' We will examine the hypothesis that SVT is exaggerated in obesity and insulin resistance and is attenuated by suppression of oxidative stress. Oxidative stress is the overabundance of reactive oxygen species and is another hallmark of hypertension, obesity, and insulin resistance. Oxidative stress can be safely reduced via intravenous infusion of ascorbic acid (Vit C) (4, 28). Therefore, we will use a randomized, double-blinded, placebo-controlled approach to test the hypothesis that elevated SVT will be attenuated by suppression of oxidative stress via ascorbic acid I.V. infusion compared with saline I.V. infusion (placebo) in obese adults with insulin resistance. Our study will identify a unique mechanism that can be targeted to reduce the excessively high prevalence of hypertension and risk for CVD in obesity and insulin resistance.

The group in the trial

  • Obese

    Treatment: ascorbic acid

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Concomitantly Higher Resting Arterial Blood Pressure and Transduction of Sympathetic Neural Activity in Human Obesity Without Hypertension
Plain-language title
Studies how nerve signals affect blood pressure in adults with obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06626113, who can take part
Record updated
3 October 2024